The ICD-10 code for pernicious anemia is D51.0, classified under “Chapter III: Diseases of the blood and blood-forming organs” in the International Classification of Diseases, Tenth Revision. This code specifically captures vitamin B12 deficiency anemia caused by intrinsic factor deficiency — the autoimmune-mediated process that defines true pernicious anemia and separates it from other B12-deficient states.
If you’re a coder, clinician, or student trying to nail down the right classification, here’s what matters: D51.0 is not a catch-all for B12 deficiency. It’s reserved for cases where the deficiency results from absent or dysfunctional intrinsic factor, typically due to autoimmune destruction of gastric parietal cells. Other forms of B12 deficiency anemia get different codes — and mixing them up causes real problems with billing, research data, and clinical decision-making.
ICD-10 Codes Related to Pernicious Anemia
One of the most common coding errors I see is lumping all B12 deficiency into D51.0. The ICD-10 system actually provides several distinct codes under the D51 category. Here’s the breakdown:
| ICD-10 Code | Description | When to Use |
|---|---|---|
| D51.0 | Vitamin B12 deficiency anemia due to intrinsic factor deficiency | Confirmed or strongly suspected autoimmune pernicious anemia |
| D51.1 | Vitamin B12 deficiency anemia due to selective malabsorption with proteinuria (Imerslund syndrome) | Rare hereditary malabsorption of B12 |
| D51.2 | Transcobalamin II deficiency | Deficiency in B12 transport protein |
| D51.3 | Other dietary vitamin B12 deficiency anemia | Vegans, strict vegetarians, or nutritional deficiency |
| D51.8 | Other vitamin B12 deficiency anemias | B12 deficiency from other specified causes |
| D51.9 | Vitamin B12 deficiency anemia, unspecified | B12 deficiency confirmed but cause undetermined |
The distinction matters. Using D51.0 tells downstream analysts and insurers that this patient has an autoimmune condition requiring lifelong B12 replacement — not a dietary issue that might resolve with supplements.
What Makes Pernicious Anemia Different from Other B12 Deficiencies?
Pernicious anemia is specifically an autoimmune disease. The immune system generates antibodies against gastric parietal cells and/or intrinsic factor itself. Without intrinsic factor, vitamin B12 cannot bind and be absorbed in the terminal ileum — regardless of how much B12 the patient consumes orally.
This is fundamentally different from someone who’s B12-deficient because they follow a strict vegan diet (D51.3) or because they’ve had gastric bypass surgery. The autoimmune mechanism carries additional clinical implications: these patients have a 2-3x increased risk of other autoimmune conditions like type 1 diabetes, thyroid disease, and vitiligo. They also carry a modestly elevated risk of gastric carcinoid tumors and gastric adenocarcinoma, which is why many hematologists recommend periodic endoscopic surveillance.
Diagnostic Criteria and Key Lab Values
Diagnosing pernicious anemia requires more than just finding a low B12 level. Here are the laboratory benchmarks that support the diagnosis and justify coding D51.0:
| Test | Expected Finding in Pernicious Anemia | Notes |
|---|---|---|
| Serum vitamin B12 | <200 pg/mL (often <100 pg/mL) | Levels 200-300 pg/mL are a gray zone; check MMA |
| Mean corpuscular volume (MCV) | >100 fL (macrocytic) | Can exceed 110-130 fL in severe cases |
| Methylmalonic acid (MMA) | Elevated (>0.4 µmol/L) | More specific for tissue-level B12 deficiency |
| Homocysteine | Elevated (>15 µmol/L) | Sensitive but not specific — also rises in folate deficiency |
| Anti-intrinsic factor antibodies | Positive in ~50-70% of cases | Highly specific (~95%) but not very sensitive |
| Anti-parietal cell antibodies | Positive in ~80-90% of cases | Sensitive but less specific; found in 5-10% of healthy elderly |
| Reticulocyte count | Low (inappropriately for degree of anemia) | Should rise dramatically after B12 replacement |
A practical point: anti-intrinsic factor antibodies are the gold standard confirmatory test. If positive, you can confidently code D51.0. If negative, the diagnosis isn’t ruled out — you just need stronger clinical correlation (autoimmune gastritis on biopsy, absent intrinsic factor on gastric secretion testing, or response to parenteral B12 with failure of oral absorption).
Clinical Presentation: More Than Just Fatigue
Pernicious anemia develops insidiously over months to years. By the time patients present, B12 stores (normally lasting 3-5 years) are deeply depleted. The classic triad involves:
- Hematological: Fatigue, dyspnea on exertion, pallor, and sometimes pancytopenia in severe cases. The peripheral smear shows macro-ovalocytes and hypersegmented neutrophils (≥5 lobes in ≥5% of neutrophils).
- Neurological: Paresthesias in hands and feet, loss of proprioception, gait ataxia, and cognitive changes. This reflects demyelination of the posterior and lateral columns of the spinal cord — subacute combined degeneration. Neurological damage can be irreversible if treatment is delayed.
- Gastrointestinal: Glossitis (a smooth, beefy-red tongue), decreased appetite, and weight loss. The underlying autoimmune gastritis may cause achlorhydria.
Here’s a clinical pearl that trips up junior clinicians: neurological symptoms can present before anemia develops. About 25-30% of patients with B12-related neurological disease have a normal hemoglobin and MCV at presentation. Don’t wait for a macrocytic blood count to check B12 in someone with unexplained neuropathy.
Treatment Protocols
Because pernicious anemia involves malabsorption by definition, intramuscular (IM) B12 injections are the standard of care. The typical regimen:
- Loading phase: Hydroxocobalamin 1000 mcg IM every other day for 2 weeks (or cyanocobalamin 1000 mcg IM daily for 7 days, then weekly for 4 weeks)
- Maintenance: Hydroxocobalamin 1000 mcg IM every 2-3 months, or cyanocobalamin 1000 mcg IM monthly — for life
There’s growing evidence that high-dose oral B12 (1000-2000 mcg daily) can achieve adequate absorption even without intrinsic factor, through passive diffusion that accounts for roughly 1% of the oral dose. A 2018 Cochrane review found oral and IM routes were similarly effective at normalizing B12 levels. Still, most hematologists — myself included — prefer IM injections for initial treatment, especially when neurological symptoms are present, and reserve oral maintenance for compliant patients who demonstrate adequate response.
Expect the reticulocyte count to peak 5-7 days after starting therapy. Monitor potassium during the first week, as rapid red blood cell production can cause transient hypokalemia.
When to See a Doctor
Seek evaluation promptly if you experience:
- Persistent fatigue that doesn’t improve with rest or iron supplementation
- Numbness, tingling, or “pins and needles” in your hands or feet
- Difficulty with balance or walking
- A sore, smooth, or unusually red tongue
- Memory problems or mood changes alongside any of the above symptoms
Ask your doctor specifically about checking a serum B12 level, CBC with differential, and methylmalonic acid. If B12 is low and pernicious anemia is suspected, anti-intrinsic factor antibodies should be tested before starting replacement therapy (treatment can interfere with antibody results).
Frequently Asked Questions
Can pernicious anemia be cured?
No. Pernicious anemia is a chronic autoimmune condition. The autoimmune destruction of parietal cells is irreversible, so patients require lifelong B12 supplementation. The good news: with consistent treatment, most hematological and many neurological symptoms fully resolve. The key is early diagnosis — neurological damage present for more than 6-12 months may be permanent.
Is D51.0 the same as general B12 deficiency?
No, and this is a critical coding distinction. D51.0 is specifically for B12 deficiency caused by intrinsic factor deficiency (pernicious anemia). A patient who is B12-deficient due to a vegan diet should be coded D51.3. If the cause is unknown, use D51.9. Accurate coding affects treatment authorization, epidemiological tracking, and clinical research validity.
How common is pernicious anemia?
Pernicious anemia affects approximately 0.1% of the general population and up to 1.9% of people over age 60. It’s more prevalent in individuals of Northern European and African descent. Women are affected slightly more than men. Because of its slow onset, many cases go undiagnosed for years — some estimates suggest the true prevalence could be 2-3 times higher than reported.
Does pernicious anemia increase cancer risk?
Yes, modestly. Patients with pernicious anemia have a roughly 2-3 fold increased risk of gastric carcinoid tumors and a mildly elevated risk of gastric adenocarcinoma due to chronic atrophic gastritis. Some guidelines recommend a baseline endoscopy at diagnosis and periodic surveillance, though the optimal interval (every 3-5 years) remains debated.
Can I use oral B12 instead of injections for pernicious anemia?
Potentially, yes — but with caveats. High-dose oral B12 (1000-2000 mcg/day) can bypass the intrinsic factor pathway through passive diffusion. Studies show this works for maintenance in motivated, compliant patients. However, for initial treatment — especially with neurological symptoms — IM injections are preferred for reliable and rapid repletion. Discuss the option with your hematologist.
